The rate of weight loss with Semaglutide GLP-1 varies from patient to patient and is influenced by factors such as starting weight, dosage, dietary habits, and overall lifestyle
A recent retrospective cohort also observed that, even in overweight patients without diabetes, the risk of primary open-angle glaucoma and ocular hypertension were significantly lower in the GLP-1RA group at both 3 and 5 years of follow-up (Vasu et al., 2025), suggesting the benefit of GLP-1RAs in the eye as an independent factor apart from blood glucose control
Follow-up Appointments Follow-up appointments at JOLI Medispa play an important role in ensuring your GLP-1 weight loss program remains safe and effective
When comparing cell sources, trade-offs in potency and safety emerge
Microdosing tirzepatide and Zepbound dosing charts Tirzepatide sold as Zepbound for obesity was studied in specific doses
Requires completion of a medical intake form and provider review